Press briefing on the conclusion of the investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events by the Pharmacovigilance Risk Assessment Committee (PRAC)

• Date:
  Thursday, 18 March 2021, All day
• Location:
  Online
  European Medicines Agency, Amsterdam, the Netherlands

Event summary

EMA is holding a virtual press briefing on the conclusion of the evaluation of a safety signal with Vaxzevria (previously COVID-19 Vaccine AstraZeneca) relating to cases of thromboembolic events by EMA’s safety committee (PRAC) on 18 March 2021.

Speakers:

• Emer Cooke (Executive Director)
• Sabine Straus (Chair of PRAC) 
• Peter Arlett (Head of Data Analytics and Methods Task Force) 

The press briefing will be moderated by Marie-Agnes Heine (Head of Communication). The press briefing will be held in English.

Video recording